Clinical trials: Estrogens
Breast Neoplasms
A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
To assess progression-free survival at the combination dose determined in the Phase 1 portion of the study, and safety of sunitinib combined with exemestane in patients with metastatic or locally-recurrent, unresectable breast…
- Trial name
- NCT00417885
- Testing
- exemestane, sunitinib malate
- Where
- 3 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Pfizer
Perimenopausal Depression, Post Menopausal
The Effects of Estrogen Withdrawal on Mood Symptoms in Women
This study evaluates the effects on mood when stopping estrogen replacement therapy. The purpose of this study is to investigate the effects of estrogen levels on perimenopausal depression.
- Conditions
- Perimenopausal Depression, Post Menopausal, Healthy, Depression
- Trial name
- NCT00060736
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Mental Health (NIMH)
Stress Urinary Incontinence
The Effect of Vaginal Estrogen Cream on Subjective and Objective Symptoms of Urodynamic Stress Incontinence
This is a randomized, double blinded placebo controlled trial over a period of 3 months. Study subjects will be randomized into 2 groups: Those receiving drug (1gm of estrogen vaginal cream [EVC] at bed time 3 times a week), and…
- Trial name
- NCT01123135
- Testing
- Vaginal ERT
- Where
- United States
- Sponsor
- University of California, Irvine
Breast Cancer
A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic activity of giredestrant in participants with Stage I-III operable estrogen receptor (ER)-positive, human epidermal growth factor receptor 2…
- Trial name
- NCT03916744
- Testing
- Giredestrant, Surgery
- Where
- 15 sites in United States, Australia and 3 more
- Volunteers
- 75 people
- Sponsor
- Genentech, Inc.
Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis.
- Conditions
- Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
- Trial name
- NCT01466114
- Testing
- estriol, Norethindrone
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of California, Los Angeles
Metastatic Breast Cancer, Estrogen-receptor-positive Breast Cancer
The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity
The goal of this clinical trial is to test a physical activity program in patients with metastatic breast cancer and overweight receiving endocrine-based treatment.
- Conditions
- Metastatic Breast Cancer, Estrogen-receptor-positive Breast Cancer, Adiposity
- Trial name
- NCT06343987
- Testing
- Physical Activity
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Aarhus University Hospital
Advanced and Metastatic Breast Cancer
Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer
This dose finding/extension study was designed originally to consist of three parts: Part A was intended to identify the MTD of the AZD2014/ palbociclib combination on a background of fulvestrant (referred to as the triplet) in…
- Trial name
- PASTOR (NCT02599714)
- Testing
- AZD2014, Palbociclib, Fulvestrant
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Breast Cancer Female, Breast Cancer
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
The purpose of this study is to test the safety and effectiveness of a sequence of drugs (a Taxane plus Trastuzumab plus Pertuzumab followed by Trastuzumab Deruxtecan, followed by Tucatinib plus Ado-Trastuzumab Emtansine (T-DM1)…
- Conditions
- Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer
- Trial name
- NCT06439693
- Testing
- Nab-Paclitaxel, Paclitaxel, Docetaxel
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Dana-Farber Cancer Institute
Postnatal Depression, Genetic Predisposition
Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression
To elucidate the disease pathway of perinatal depression by identifying genetic variants which could play a role in predisposing to the condition and/or lead to better understanding of the pathogenesis of the condition.
- Trial name
- NCT02373709
- Where
- Singapore
- Volunteers
- 750 people
- Sponsor
- KK Women's and Children's Hospital
Breast Cancer, Hot Flashes
Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy
RATIONALE: Estrogen can relieve the symptoms of menopause, but can also cause the growth of breast cancer cells. Flaxseed may reduce the number of hot flashes and improve mood and quality of life in postmenopausal women not…
- Conditions
- Breast Cancer, Hot Flashes, Menopausal Symptoms, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00956813
- Testing
- flaxseed
- Where
- 107 sites in United States
- Volunteers
- 210 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients
Endocrine therapy is the mainstay of systemic treatment in patients with endocrine responsive breast cancer. Aromatase inhibitors are the most active agents in post-menopausal women.
- Trial name
- NCT00954135
- Testing
- letrozolo+cyclophosphamide, letrozolo+sorafenib+cyclophosphamide
- Where
- 2 sites in Italy
- Volunteers
- 190 people
- Sponsor
- University of Turin, Italy
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
This phase II trial studies how well anastrozole and letrozole after surgery work in treating patients with stage I-III breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04294225
- Testing
- Anastrozole, Letrozole
- Where
- 3 sites in United States
- Volunteers
- 161 people
- Sponsor
- Mayo Clinic
Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or…
- Conditions
- Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer
- Trial name
- NCT02567396
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Sponsor
- National Cancer Institute (NCI)
Advanced Breast Cancer
A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer
This study is an open-label, multicenter, Phase Ib/II clinical trial designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic characteristics of QLC1401 tablets in combination with CDK4/6 inhibitors or mTOR…
- Trial name
- NCT07173556
- Testing
- QLC1401
- Volunteers
- 96 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Oral Contraceptive
Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation
The purpose of this research study is to gain a better understanding of the changes that may occur in the breast when a woman uses an oral contraceptive (birth control pill).
- Trial name
- OCP2 (NCT01318005)
- Testing
- Oral Contraceptive: Ortho-Novum® 1/35, Oral Contraceptive: Ovcon® 35, Oral Contraceptive: Microgestin Fe® 1/20
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Carcinoma, Ductal, Breast, Breast Cancer Female
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
This is a study to investigate the potential clinical benefit of G1T48 as an oral selective estrogen receptor degrader (SERD) alone and in combination with palbociclib, a cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, in…
- Conditions
- Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Neoplasm, Breast Cancer
- Trial name
- NCT03455270
- Testing
- G1T48, Palbociclib
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 107 people
- Sponsor
- G1 Therapeutics, Inc.
Breast Cancer
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
Hormone receptor-positive breast cancer accounts for about 70% of all breast cancers. Extended endocrine therapy with aromatase inhibitor is the current main treatment for hormone receptor-positive breast cancer.
- Trial name
- NCT04476485
- Testing
- endocrine therapy
- Where
- 12 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Shengjing Hospital
Breast Cancer
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer.
- Trial name
- NCT05654532
- Testing
- AC699
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Accutar Biotechnology Inc
Menopause Surgical
Hormonal Regulation of Cardiometabolic Health Study
The goal of this observational study is to understand how the loss of ovarian function after oophorectomy affects the health and well being of women aged 35-50. The study focuses on four areas: 1.
- Trial name
- HoCa (NCT07406412)
- Testing
- Surgical removal of ovaries, Hormone Replacement Therapy (HRT)
- Where
- 7 sites in Finland
- Volunteers
- 120 people
- Sponsor
- University of Jyvaskyla
Healthy
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women
The primary objective is to determine the effect of a high-fat meal on the bioavailability and PK of a single, oral dose of BZA/CE (PNP) 20mg/0.625 strength tablet, assessing both the BZA and CE components.
- Trial name
- NCT00465075
- Testing
- Bazedoxifene/conjugated estrogens combination
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer